News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

LEAD Therapeutics, Inc. and ShangPharma in Strategic Relationship


11/14/2007 11:15:05 AM

November, 14, 2007 -- LEAD Therapeutics, Inc., has established a two-way strategic research collaboration with ShangPharma of China. The investment division of ShangPharma, China Gateway Life Science (Holding) Ltd., will make an equity investment of unspecified size in LEAD Therapeutics. LEAD Therapeutics will turn around and use a division of ShangPharma as the CRO for its drug development projects, providing 20 to 30 scientists who will work exclusively on LEAD's projects. More details...

Read at ChinaBio Today

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES